EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
KPC Pharmaceuticals EBITDA Margin % Related Terms
KPC Pharmaceuticals EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for KPC Pharmaceuticals's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, KPC Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
KPC Pharmaceuticals EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, KPC Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where KPC Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KPC Pharmaceuticals (SHSE:600422) has a EBITDA Margin % of -15.50% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on KPC Pharmaceuticals and its competitors. Over the past decade, KPC Pharmaceuticals' EBITDA Margin % has ranged from 3.99 to 13.81. According to the industry distribution chart, KPC Pharmaceuticals ranks #663 out of 952 companies in the Drug Manufacturers industry, placing it in the top 69.6%.
Is KPC Pharmaceuticals' EBITDA Margin % too high?
KPC Pharmaceuticals' current EBITDA Margin % is -15.50%. Over the past 10 years, this metric has ranged from a low of 3.99 to a high of 13.81. Based on the distribution chart, KPC Pharmaceuticals ranks #663 out of 952 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, KPC Pharmaceuticals has a GF Score™ of 62/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does KPC Pharmaceuticals' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, KPC Pharmaceuticals ranks #663 out of 952 companies for EBITDA Margin %. This places KPC Pharmaceuticals in the lower half of its industry. The industry median EBITDA Margin % is 12.47. Historically, KPC Pharmaceuticals' own EBITDA Margin % has ranged from 3.99 to 13.81 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on KPC Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. KPC Pharmaceuticals's current EBITDA Margin % is -15.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is KPC Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, KPC Pharmaceuticals (SHSE:600422) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥11.77, compared to a current price of ¥7.70 — trading 34.6% below its estimated fair value. The current EBITDA Margin % is -15.50%. KPC Pharmaceuticals' overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For KPC Pharmaceuticals (SHSE:600422), the current EBITDA Margin % is -15.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is KPC Pharmaceuticals (SHSE:600422) Overvalued in 2026?
Based on GuruFocus' analysis, KPC Pharmaceuticals stock appears to be undervalued.
The current stock price of ¥7.70 is trading 34.6% below its estimated GF Value™ of ¥11.77.
GuruFocus considers KPC Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for SHSE:600422:
EBITDA Margin %: -15.50%
GF Value™: ¥11.77 vs. price of ¥7.70 (34.6% below fair value)
No single metric tells the full story. See the SHSE:600422 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
KPC Pharmaceuticals Inc is a pharmaceutical company which focused on innovative natural botanical drugs in China. Its business scope covers traditional Chinese medicine, chemical medicine, and medicinal circulation. Its products include Panax notoginseng, gastrodine, artemether, and special botanical drugs.
62GF Score
Get the complete analysis for SHSE:600422
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600422 has been successfully added to your 
